

| | | |
|---|---------------------------------|--------------------------|
| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Atty. Docket No. 072396.0162 | Serial No. 09/244,792 |
| | Applicant Aldo T. Iacono | |
| | Filing Date 2/5/1999 | Group 1614 |
| | Examiner Wang, Shengjun | |

| Exam Initial | No. | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|--------------|-----|---|
| SW | 5 | Desai et al.. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharm Res. 2003 20(3):442-447. |
| | 6 | Fahr et al., Liposomal formulations of Cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics, Crit Rev Ther Drug Carrier Syst., 2001, 18(2):141-172. |
| | 7 | Gilbert et al., Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol, Am J Respir Crit Care Med. 1997, 156(6):1789-93. |
| | 8 | Harrington et al., Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol. 2002, 54(12):1573-1600. |
| | 9 | Iacono et al., 2006, A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients, N. Engl. J. Med. 354:141-150. |
| | 14 | Kahan, Cyclosporine, N Engl J Med. 1989, 321(25):1725-38. |
| | 15 | Keenan et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997; 113:335-330. |
| SW | 16 | Klyashchitsky et al., Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine, J Drug Target. 1999, 7(2):79-99. |

558405

Examiner

S. Wang

Date Considered

11/8/06

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|--------------------------|
| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Atty. Docket No. 072396.0162 | Serial No. 09/244,792 |
| | Applicant Aldo T. Iacono | |
| | Filing Date 2/5/1999 | Group 1614 |
| | Examiner Wang, Shengjun | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|--|--------------|---------|---------------|-------|----------|-----------------------|
| Exam Initial | No. | | Document No. | Date | Country | Class | Subclass | Translation Yes No |
| SW | 12 | | WO9804279 | 2/5/98 | International | | | |
| SW | 13 | | WO9942124 | 8/26/99 | International | | | |
| | | | | | | | | |
| | | | | | | | | |

| Exam Initial | No. | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|--------------|-----|--|
| SW | 1 | Bolling et al., Local cyclosporine immunotherapy of heart transplants in rats enhances survival, J Heart Lung Transplant. 1991 10(4):577-83. |
| | 2 | Bridges et al., An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm. 2000 204(1-2):69-79. |
| | 3 | Corcoran et al. Aerosol cyclosporine provides dose dependent improvement in lung function after lung transplantation. J. Heart Lung Transplant Abstracts 2003; 22:S77. |
| SW | 4 | DeCamp, Jr., Inhaled Cyclosporine - A Breath of Fresh Air?" N. Engl. J. Med. 2006, 354:191-193. |

| | | | | |
|--------|----------|---------|-----------------|----------|
| 558405 | Examiner | S. Wang | Date Considered | 11/18/06 |
|--------|----------|---------|-----------------|----------|

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|--------------------------|
| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Atty. Docket No. 072396.0162 | Serial No. 09/244,792 |
| | Applicant Aldo T. Iacono | |
| | Filing Date 2/5/1999 | Group 1614 |
| | Examiner Wang, Shengjun | |
| | | |

| Exam Initial | No. | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|--------------|-----|---|
| SW | 17 | Lee et al., Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles, Int J Pharm. 1999, 191(2):87-93. |
| | 18 | Letsou et al., Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression, Ann Thorac Surg. 1999 68(6):2044-2048. |
| | 19 | Nunley et al., Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients, Chest, 1998, 113(5):1235-43. |
| | 20 | O'Riordan, Formulations and nebulizer performance, Respir Care. 2002, 47(11):1305-1312. |
| | 21 | O'Riordan et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995; 151:516-521. |
| | 22 | Patton, Deep-lung delivery of proteins, Modern Drug Discovery, 1998, 22:19-28. |
| | 23 | Rauscher, Aerosol Cyclosporine Preserves Lung Function in Transplant Recipients, May 23, 2006, Reuters Health. |
| | 24 | Smaldone et al., Deposition of aerosolized pentamidine and failure of pneumocystis prophylaxis, Chest. 1992, 101(1):82-87. |
| SW | 32 | Waldrep et al., Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety Chest. 1997, 111(2):316-23. |

| | | |
|--------|--------------------|--------------------------------|
| 558405 | Examiner <i>SW</i> | Date Considered <i>11/8/08</i> |
|--------|--------------------|--------------------------------|

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---------------------------------|--------------------------|
| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Atty. Docket No. 072396.0162 | Serial No. 09/244,792 |
| | Applicant Aldo T. Iacono | |
| | Filing Date 2/5/1999 | Group 1614 |
| | Examiner Wang, Shengjun | |

| U.S. PATENT DOCUMENTS | | | | | | | | |
|-----------------------|-----|--------------|----------|---------------|-------|----------|--------------------------------|--|
| *Exam. Initial. | No. | Document No. | Date | Name | Class | Subclass | Filing Date if Approximate. | |
| SW | 25 | 4,996,193 | 2/26/91 | Hewitt | — | — | | |
| | 26 | 5,654,007 | 8/5/97 | Johnson et al | — | — | | |
| | 27 | 5,688,824 | 11/18/97 | Williams. | — | — | | |
| | 28 | 5,719,123 | 2/17/98 | Morley et al. | — | — | | |
| | 29 | 5,780,014 | 7/14/98 | Eljamal | — | — | | |
| | 30 | 5,814,607 | 9/29/98 | Patton | — | — | | |
| SW | 31 | 6,572,893 | 6/3/03 | Gordon et al | — | — | | |
| | | | | | | | | |
| | | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|--------------|---------|---------------|-------|----------|-----------------------|--|
| Exam Initial | No. | Document No. | Date | Country | Class | Subclass | Translation Yes No | |
| SW | 10 | WO9800111 | 1/8/98 | International | — | — | | |
| SW | 11 | WO9801147 | 1/15/98 | International | — | — | | |

| |
|--|
| 558405 |
| Examiner <u>S. Wang</u> Date Considered <u>11/7/06</u> |

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.